Business
Veru Announces Presentation of Preclinical Evidence Supporting the Therapeutic Benefit of Enobosarm Alone or in Synergistic Combination with a CDK4/6 Inhibitor Against Palbociclib Resistant Metastatic Breast Cancer at the 2021 San Antonio Breast Cance...
Veru Announces Presentation of Preclinical Evidence Supporting the Therapeutic Benefit of Enobosarm Alone or in Synergistic Combination with a CDK4/6
About this update from Veru Inc.
[{"type":"text","content":"Veru Announces Presentation of Preclinical Evidence Supporting the Therapeutic Benefit of Enobosarm Alone or in Synergistic Combination with a CDK4/6 Inhibitor Against Palbociclib Resistant Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer Symposium \n MIAMI, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast cancer and prostate cancer, today announced that human preclinical data will be presented demonstrating that enobosarm treatment alone as well as in combination with a CDK4/6 inhibitor increased androgen receptor (AR) expression resulting in the synergistic suppression of breast cancer cell and tumor models that are resistant to CDK4/6 inhibitors and estrogen blocking agents. Enobosarm is an oral, first-in-class, selective androgen receptor targeted agonist for the androgen receptor, a tumor suppressor, being evaluated in Phase 3 clinical studies to treat AR+ER+HER2- metastatic breast cancer without unwanted masculinizing side effects. The presentation was selected as a spotlight presentation at the San Antonio Breast Cancer Symposium being held December 07-10, 2021, in San Antonio, TX. Highlights of the presentation: Utilizing a human PDX model (CTPx4353) that was derived from a liver metastasis in a patient that had received and progressed on fulvestrant, palbociclib and an aromatase inhibitor (resistant to both a CDK 4/6 inhibitor and estrogen blocking agents), enobosarm monotherapy significantly reduced the growth of the tumors. The combination of palbociclib and enobosarm treatment was synergistic and resulted in the almost complete inhibition of the growth of the tumors in the human PDX AR+ER+ breast cancer model (CTPx4353). Palbociclib treatment alone had no effect on tumor growth. Interestingly, both palbociclib and enobosarm each had the ability to significantly increase the expression of the androgen receptor in breast cancer cell lines and tumors. This study provides preclinical evidence to support the synergistic therapeutic benefit of the CDK4/6 inhibitor and enobosarm combination therapy in clinically relevant models of CDK4/6 inhibitor and estrogen blocking agent resistance breast cancer. This treatment strategy is being evaluated in the Phase 3 ENABLAR-2 clinical study of abemac...